Bruno
GA Member
- Jul 1, 2018
- 2,718
| TYPE | Research & Development |
| COUNTRY | Spain |
| PROJECT | Lyme Disease Vaccine - SP-LYMEVAX-01 - Exploratory |
| PROJECT COST | 200,000,000.00 |
| COMPLETION DATE | 6/11/2020 |
| PROJECT INFORMATION | Lyme Disease is still without a preventable cure, as such the Agency of Medicines and Medical Devices will start a exploratory research to find the best possible candidate for a vaccine that may work to facilitate or induce a antibody response to the disease, especially in vitro, that will permanently make a person without the disease imune. Various techniques will be explored and tested which will be looked at by the Experts and Researchers inside the agency, in which the best 3 candidates will follow up to pre-clinical trials on animals. The Exploratory phase consists of basic lab research and the identification of natural or synthetic antigens, which alert the body to harmful pathogens (Bollmann). If it shows promise in the exploratory phase, it moves on to the animal testing phase, after being approved by the Agency. Currently Lyme disease is caused by the bacterium Borrelia burgdorferi and rarely, Borrelia mayonii. It is transmitted to humans through the bite of infected black legged ticks. Typical symptoms include fever, headache, fatigue, and a characteristic skin rash called erythema migrans. If left untreated, infection can spread to joints, the heart, and the nervous system, and can be fatal. Lyme disease is diagnosed based on symptoms, physical findings (e.g., rash), and the possibility of exposure to infected ticks. |
| PRIVATE / ENCRYPTED | No |
